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ABSTRACT 
Background: Substance use disorders are a highly prevalent group of 
chronic diseases with devastating individual and public health 
consequences. Current treatment strategies suffer from high rates of 
relapse, or return to drug use, and novel solutions are desperately needed. 
Realize Analyze Engage (RAE) is a digital, mHealth intervention that 
focusses on real time, objective detection of high-risk events (stress and 
drug craving) to deploy just-in-time supportive interventions. The present 
study aims to (1) evaluate the accuracy and usability of the RAE system 
and (2) evaluate the impact of RAE on patient centered outcomes. 
Methods: The first phase of the study will be an observational trial of N = 
50 participants in outpatient treatment for SUD using the RAE system for 
30 days. Accuracy of craving and stress detection algorithms will be 
evaluated, and usability of RAE will be explored via semi-structured 
interviews with participants and focus groups with SUD treatment 
clinicians. The second phase of the study will be a randomized controlled 
trial of RAE vs usual care to evaluate rates of return to use, retention in 
treatment, and quality of life. 
Anticipated findings and future directions: The RAE platform is a potentially 
powerful tool to de-escalate stress and craving outside of the clinical 
milieu, and to connect with a support system needed most. RAE also aims 
to provide clinicians with actionable insight to understand patients’ level 
of risk, and contextual clues for their triggers in order to provide more 
personalized recovery support.  
KEYWORDS: substance use disorder; stress; craving; mHealth; wearable; 
digital health; digital diagnostics; digital therapeutics 
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INTRODUCTION 
Substance use disorders (SUDs) compose a group of chronic relapsing 
diseases, characterized by recurrent use of substances (including alcohol 
and recreational drugs) leading to negative physical, social, legal and 
financial consequences [1]. In 2018, 20.3 million Americans suffered from 
a SUD [2], resulting in staggering healthcare costs. As with other chronic 
diseases, SUDs can be treated. However the efficacy of traditional 
treatment options, which largely focus on a combination of behavioral and 
pharmacologic therapies, is limited by the relapsing nature of the disease. 
It is estimated that an average of 40–60% of individuals in recovery will 
have an episode of return to drug use (or relapse), with rates for some 
SUDs reported as high as 91% [3]. Although return to use is an 
acknowledged aspect of the recovery process, it represents a dangerous 
and potentially lethal situation: for example, individuals who return to 
opioid use after a period of abstinence are at an increased risk of overdose 
due to their decreased tolerance. Though treatment programs instill 
techniques for recognizing and avoiding drug use triggers, these may be 
difficult to apply in real world settings when patients are outside the 
protected clinical environment.  
Stress is a documented risk factor for return to drug use. For 
individuals with SUD, stress can mimic a withdrawal like state and can 
lead to poor decision making [4,5]. Stress has been positively correlated to 
craving for opioids, cocaine and tobacco, and to drug relapse in 
individuals in treatment for SUD [6–9]. Stress is therefore indicative of 
high-risk periods in recovery, and the identification of stress may predict 
risk of relapse in susceptible individuals. Craving, or the subjective 
experience of wanting to use a drug, is another important behavioral 
phenomenon to consider in recovery—it is included in the DSM-IV 
diagnosis of SUD, is a strong predictor of return to use, and carries an 
interesting, likely bidirectional, relationship to stress [5,10–12]. That is, 
craving may be precipitated by or induce stress, and the two states share 
some physiological characteristics. Both stress and craving manifest 
physiologic changes that can be detected as digital biomarkers by 
wearable biosensors and can reveal prime opportunities for real time 
adaptive intervention [13]. Addressing stress via structured interventions, 
such as mindfulness exercises, has demonstrated significant positive 
effects on treatment success [14,15]. Similarly, overall mindfulness has 
been inversely correlated with craving, and mindfulness based 
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interventions have been shown to decrease drug craving in multiple trials 
[16–18].  
Current treatment protocols largely fail to tap into the potential of 
mHealth as a powerful tool to combat addiction. Wearable sensors are 
noninvasive devices that are capable of detecting the biomarkers 
associated with stress and craving. Many of these wearable sensors are 
commercially available smart watches and are well-received by patients [19–
21]. Wearable sensors are already under investigation for the detection and 
treatment of a number of clinical disorders, such as epilepsy, PTSD, 
suicidality, cardiac arrythmias, stress and drug abuse [22–31]. mHealth 
capitalizes on the burgeoning industry of mobile applications (apps) and 
wearable sensors to connect clinicians and patients, to understand 
behaviors and experiences in natural environments, and to offer real time 
interventions.  
Early work efforts in the development of mHealth based tools for SUDs 
have encountered challenges, including limited accuracy of digital 
biomarker detection, acceptability of digital health tools by consumers, 
privacy issues regarding continuous monitoring and data streaming, lack 
of standard methods for analysis, and implementation barriers. Despite 
barriers however, mobile health technologies are rapidly becoming more 
sophisticated, and are showing increasing promise in treatment 
paradigms. Prior studies have demonstrated the usability, efficacy and 
acceptability of technology-based interventions to support individuals in 
recovery from SUD [13,32–35]. For example, Gustafson et al. have 
demonstrated the efficacy of a mobile phone app to decrease risky 
drinking days and increase likelihood of abstinence in alcohol use 
disorder (AUD) [33]. The mobile app (ACHESS) uses cravings based on 
ecological momentary assessment (EMA) and geolocations to trigger 
personalized feedback and support. In marijuana users, Monney et al. 
found the Stop-cannabis app, which delivers personalized messages based on 
self-reported marijuana use, demonstrated high perceived usefulness and 
high acceptability [35]. Although mobile apps are common, few mHealth 
interventions leverage continuous physiologic sensors to trigger 
interventions. One such system, described by Leonard et al., also used a 
mobile app (Mind the Moment) for AUD combining EMA with physiologic 
data (electrodermal activity from a wearable sensor) to trigger their 
personalized messages and education [34]. In a pilot study of young adults, 
acceptability and perceived helpfulness of the app were high. However to our 
knowledge no intervention exists to combine objective detection of multiple 
markers of risk with real time support in addition to de-escalation tools.  
An urgent need exists for treatment options that immediately identify 
periods of high risk, predict relapse, and intervene in real time- before 
relapse occurs. We propose Realize Analyze Engage (RAE) as a solution to 
bridge this gap in treatment. RAE is the first mHealth intervention to our 
knowledge to utilize a wearable sensor for continuous monitoring of stress 
and craving detection with real-time mobile interventions. RAE provides 
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an approach to substance use treatment by combining digital detection of 
high-risk stress periods and drug use (to help users REALIZE and ANALZYE 
these to critical states), with interventions, support and trend reporting (to 
help users ENGAGE in their treatment program). The ability of clinicians 
to tailor interventions for individuals in recovery based on monitoring of 
physiologic parameters has the potential to prevent relapse, improve rates 
of sustained recovery, and save lives compared to current treatment 
paradigms. The present study aims to 1) evaluate the accuracy of stress 
and craving detection within RAE, and to assess usability of RAE from the 
patient and clinician standpoint and 2) evaluate the impact of RAE on 
outcomes of return to drug use, retention in treatment and quality of life. 
RAE SYSTEM ARCHITECTURE 
The RAE system (Figure 1) is an innovative mHealth intervention for 
individuals in recovery for SUD that combines objective metrics with 
digital therapeutics to promote sobriety and self-efficacy through behavior 
modification. The RAE system consists of (1) a wearable device that 
continuously measures physiology (2) an interactive mobile app that 
offers dialectical behavior therapy (DBT)-based interventions to promoted 
mindfulness upon stress or craving detection in wearable sensor data, and 
(3) a clinical portal to aggregate data, provide monitoring capabilities and 
provide actionable insight to treatment providers. The RAE systems (app 
and clinical portal) are HIPAA, HITECH Act and CFR 42 part 2 compliant. 
 
Figure 1. RAE System Architecture. 
The RAE system was developed by a team of physicians, engineers, web 
and app developers based on several years of preliminary work. The 
patented algorithm for the detection of stress and craving is based on a 
pilot study in 30 individuals in recovery from SUD conducted at two 
outpatient treatment centers in New England [13]. In the pilot study 
participants wore a wore a wrist-mounted wearable sensor that measured 
electrodermal activity (skin conductance), tri-axial accelerometry (i.e., 
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locomotion in three directions) , heart rate, heart rate variability, and skin 
temperature for four days, and self-reported episodes of stress and craving. 
A total of 25 features were obtained from the five sensor datastreams. 
Forty-minute segments of data surrounding events (20 min pre- and 20 
min post- self-reported stress or craving), and were analyzed using a 5-min 
siding window operation. Based on the features using shape and scale 
derived from accelerometer and heart rate data from our preliminary 
work, we are able to differentiate stress from non-stress condition with an 
accuracy of 74.5%, and cravings from no-cravings with an accuracy of 
75.7% using Fine Gaussian Support Vector Machine model.  
The workflow, interaction components and aesthetic of RAE were 
iteratively refined based on input from target end users—both patients in 
SUD treatment and providers. Specifically, semi-structured interviews 
were conducted with the 30 participants from the pilot study to assess 
acceptability, barriers and facilitators to sensor-based monitoring. 
Participants were also allowed to demo the app and provide feedback 
(although the working app was not available to use it he initial pilot). Two 
focus groups with treatment staff (N = 6 in each group) were conducted to 
assess needs, potential integrations into workflow, and was used to refine 
and develop the app and clinical portal. 
The Wearable Sensor  
The first component of the RAE system is a wrist worn wearable sensor 
to continuously detect physiologic data, which are streamed continuously 
via Bluetooth connection to the RAE app. The current version of the app 
pairs with the Garmin Vivosmart 4 (Figure 2, Garmin, Olathe, KS, USA). The 
Vivosmart 4 is equipped with a barometric altimeter, tri-axial 
accelerometer, heart rate monitor, and pulse oxygenation sensor. The 
Vivosmart 4 has a touch screen interface, has up to 7 days of battery life, 
is waterproof, and also functions as a standard fitness tracker, making it 
appealing to RAE users. Future iterations of the RAE app will be device 
agnostic and able to connect to other popular commercially available 
smartwatches that include the minimum required sensor components. 
 
Figure 2. Garmin Vivosmart 4. 
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RAE Mobile Phone Application 
The RAE mobile application (Figure 3) is available for Android and iOS. 
The app includes interactive tools that are prompted when an event of 
interest is detected based on wearable sensor or phone sensor data (i.e., 
stress, craving, or physical proximity to a location). Tools can also be 
manually initiated by the user at their discretion. Features of the RAE app 
include de-escalation tools, geolocation based monotiling tools, and 
general health monitoring tools.  
 
Figure 3. RAE Mobile App. 
De-escalation tools 
The RAE app offers a journaling tool with multiple DBT based prompts. 
These are automatically requested once an event has been detected, but 
can also be accessed on demand. Journal prompts focus on current 
circumstances and emotions, the users perceptions of them and their 
intensity rating. Journal entries are intended to promote mindfulness and 
to serve as a data collection tool understand patterns and triggers. Users 
also have access to a brief, guided breathing tool to help de-escalate 
perceived stress. Finally, upon detection of stress or craving based on our 
patented algorithm, the app will offer the user emergency help in the form 
of an audio or video call to one of their pre-defined support persons. These 
may be personal contacts or providers from their treatment program (e.g., 
case managers, peer recovery coaches). If the selected contact is a 
healthcare provider in a telehealth enabled treatment program who is 
“available” in the portal, an option to request an emergency telehealth 
visit is presented. 
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Check in and location monitoring tools 
This feature uses geolocation to monitor both desirable locations to 
demonstrate accountability and build trust during recovery, and 
undesirable locations to provide support. Manual check-ins can be 
initiated by the user to demonstrate presence at location important to 
treatment success (for example checking in at their place of employment 
on time, or checking in to a 12-step group meeting). Areas considered high 
risk (e.g., a familiar liquor store) can be pre-programmed in the app by a 
clinician, and will trigger an alert if the patient’s phone comes within at 
least 100 meters of the tagged location. When either of these features are 
engaged, the geocoded location is then logged in the app. Both prompt 
supportive messages that align with treatment goals. For example a check 
in at a meeting will prompt praise for continuing to meet treatment goals, 
and a detection in a risky location will prompt a personalized motivational 
message with a reminder engage their support network if needed. 
Geocoded location for any detected or manually entered stress or craving 
event it also logged in the RAE system. 
General health monitoring tools 
Quality and duration of sleep and physical activity as detected by the 
wearable are also recorded by the app. Events, activity, sleep, and location 
are plotted over time in the calendar with color coding schemes to provide 
insight into temporal, situational and geographic relationships. 
The RAE Clinical Portal  
The RAE Clinical Portal (Figure 4) will be accessible only by treatment 
providers and will capture all data from the user. The portal maintains 
historical data and provides real-time updates on client status. Data from 
the participant’s app will be pushed to the clinical portal upon completion 
of any user interaction or when the device is charging. Clinicians will only 
have access to their assigned clients. They will be able to view information 
such as stress/craving trends, journal responses, and geolocation which 
can help inform their treatment plan. Treatment providers will have at-a-
glance access to a home dashboard for their patient list and pending alerts, 
and individual patient-level data (recorded stress and craving events, 
extent and content of user interaction, participant use and compliance, 
sleep, activity, and visualizations to place stress and craving events in 
context). The RAE clinical portal will also generate patient reports and 
summaries in various formats that can be integrated into the electronic 
medical record for harmonization with the reminder of their clinical 
record.  
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Figure 4. RAE Clinical Portal Home Screen. 
METHODS 
Specific Aims 
Our proposal has two specific aims. Our first aim is to deploy and 
optimize the RAE system in a population of individuals in treatment for 
SUD. By integrating the RAE system into an active treatment program, we 
will evaluate the sensitivity/specificity of the detection algorithms in 
natural environments and collect data on usability from both participants 
and clinicians. Data from Aim 1 will be used to optimize the accuracy, 
usability, and compliance of the RAE system. We anticipate that data 
collection for Aim 1 will take 12 months, and that preliminary data 
analysis will be complete by June 2021. Prior to advancing to Aim 2 we will 
achieve preset milestones for accuracy of the stress detection algorithm 
and user compliance with the RAE system. Our second aim is to 
demonstrate the impact of the RAE system on outcomes in SUD. After 
optimization of the RAE system in Aim 1, we will deploy the technology in 
a multi-site, randomized controlled trial (RCT) to measure impact on 
relapse rates, engagement/retention in treatment programs, and 
psychosocial factors.  
Aim 1: Observational Trial for Accuracy and Usability  
This study is approved by the institutional review board at the 
University of Massachusetts Medical School. A convenience sample of N = 
50 participants will be recruited through multiple outpatient SUD 
treatment programs across the US. Five recruitment sites have been 
selected to increase gender, socioeconomic, and ethnic diversity in the 
sample. Sites vary by client payer mix (predominantly private pay vs 
predominantly public insured), and geographic region (two sites in the 
northeast, one site in the southeast, one site in the Midwest and one site in 
the west). All sites include both MOUD and non-MOUD treatment options. 
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We will aim to recruit approximately 50% female participants, and a 
minimum of 20% African American/Black and 20% Latinx participants.  
Eligible participants will be at least 18 years old, enrolled in an 
outpatient SUD treatment program, have an iOS or Android capable smart 
phone, able to communicate in English and able to provide informed 
consent. We will exclude individuals with a limitation of the non-
dominant upper extremity (such as amputation or fracture). During the 
enrollment visit, study staff will obtain informed consent, and will assist 
the participant with downloading the RAE app onto their phone and 
pairing the sensor with the app. Participants will be given a brief (10 min) 
tutorial on app usage, including logging stresses and cravings, adding 
contacts, and inputting journal entries.  
During the 30-day active study period, participants will be asked to 
wear the sensor at all times except when charging (typically required for 
2–3 h every 5–7 days), as the sensor can safely be worn during normal 
activities including showering. Participants will be instructed to keep the 
RAE app open, and to interact with the RAE application when prompted 
by a notification or when they perceive stress or craving that was not 
detected by the RAE system. Study staff will conduct check in calls with 
participants every ten days in order to ensure compliance with the 
protocol, troubleshoot any technical issues, and to gather acceptability and 
usability data. Participants will also have access to study staff via phone, 
test and email during business hours for any troubleshooting or technical 
difficult. . At the end of the active study protocol, study staff will conduct a 
semi-structured interview to gather feedback on user experiences.  
Data Collection 
Quantitative data collection 
Biometric (physiologic) data will be captured through the wearable 
sensor, streamed through the RAE app, and stored in a secure Amazon 
Web Services (AWS) server. Biometric data at key events will be analyzed, 
including: false positives (defined as a sensor detected event where the 
user response “No Stress/No Craving/Neutral” when prompted), true 
positives (defined as a sensor detected event that the user responds “Yes” 
to the prompted screen upon detection of stress or craving) and false 
negatives (defined user manually indicates stress or craving that has not 
been detected by the sensor). Demographic and historical data (including 
substance use history, medical history and psychiatric history) will be 
obtained at baseline. Throughout the study period, we will collect data on 
system compliance (number of hours per day of active data collection), 
number of interactions with the device (both prompted by device 
detection and unprompted), number of events detected, and degree of user 
interaction with the app (choice to interact or ignore, choice of interaction 
type, etc.).  
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Data on treatment related outcomes will be collected both through self-
report and provider report at 30 days, and three, six, and twelve month 
follow ups. These include relapse to use of the drug for which they are 
receiving treatment (either via self-report or positive routine drug screen 
per treatment protocol), retention in treatment program, emergency 
department visits, and need for inpatient admission.  
Assessments of functional status (with respect to education, 
employment, and legal issues), mental health status and positive changes 
in social values and networks will also be evaluated at multiple timepoints. 
To assess the impact of RAE on important psychosocial factors, we will 
utilize standardized assessment tools to obtain a more comprehensive 
picture of the participants’ overall health at baseline, after the 30-day 
active study period, and at three, six and twelve month follow up phone 
calls. These tools will include: The World Health Organization Quality of 
Life (WHOQOL) Brief tool [36–38], the Behavior and Symptom 
Identification Scale (BASIS-24) [39,40], and the Brief Addiction Monitor 
(BAM) [41]. The WHOQOL Brief is a 26-item questionnaire that focuses on 
individual perceptions on satisfaction with life related to physical health, 
psychological status, social relationships and environment. The WHOQOL 
Brief which has been well validated across a variety of medical and 
psychiatric conditions. The BASIS-24 is a validated self-report measure of 
mental health symptoms, relationships and ability to function in domains 
related to those symptoms. The BAM is a validated, 17 item self-report 
measure that to assess substance use disorder treatment progress and 
evaluates recent substance use, risk of return to substance use, and 
recovery protective factors. 
Qualitative data (exit interviews and focus groups) 
Data on the usability, acceptability, and overall perceptions of the RAE 
system will be gathered by semi-structured exit interviews with individual 
RAE participants. Topic areas will include perception of stress and craving, 
usability and acceptability of the RAE system, user experience, degree to 
which interactions were bothersome, degree to which continuous 
physiologic monitoring and/or RAE interactions affected behavior, and 
future implications and uses. Two focus groups will be conducted with 6-
10 SUD treatment clinicians from the recruitment sites; once when 50% 
target enrollment is reached then again once 100% target individual 
enrollment is reached. We will specifically aim to engage treatment 
providers who have been involved with study participants, however will 
also invite treatment providers who have never seen RAE as well. During 
focus groups, the clinicians will receive demonstrations on the study 
devices, RAE clinical portal, and RAE mobile application. Topic areas will 
include current treatment provider needs amendable to digital 
interventions, initial impressions of the mobile app/clinician portal, RAE 
workflow integration, and barriers/facilitators to RAE implementation 
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into practice. Interviews and focus groups discussions will be audio 
recorded, then transcribed verbatim. 
Data Analysis 
Machine learning of biometric data, evaluation of participant 
characteristics, and compliance 
A machine-learning framework will be developed with features 
derived from sensor accelerometer as well as heart rate data using Hilbert 
transform and wavelet transform approaches. The features include shape 
and scale of the amplitude distribution of the accelerometer data along 
with nonlinear features of other available signals [28]. The algorithm will 
initially be evaluated using 10-fold cross validation, and subsequently be 
split into training and test data sets as sufficient data become available. 
The machine learning paradigm will provide us with a classifier that can 
distinguish stress and cravings from non-stress conditions. Models will be 
evaluated by standardized metrics of sensitivity, specificity and Area 
Under the Curve (AUC) for the Receiver Operating Characteristics (ROC) 
curve. Our goal is to improve upon our base algorithm an AUC value of 0.8 
or above. We will improve the performance of these standard classifiers 
with features based on the nonlinear characteristics of the data and if we 
cannot achieve the desired performance, we will advance to deep learning 
methods. Individual participant and treatment characteristics associated 
with detection accuracy and system compliance will be explored to 
identify both at-risk individuals and characteristics that would indicate 
need for a tailored approach. Specifically, we will evaluate the effect of 
gender, substance of choice, medications for opioid use disorder (MOUD, 
i.e., methadone, buprenorphine, and/or naltrexone), and age on digital 
biomarkers and compliance.  
Overall rates of compliance with the system will be calculated, 
including the hours per day of use (based on biometric data capture) and 
the frequency and extent to which participants respond to the RAE system 
prompts. In addition, Relative Subjective Count (RSC), the quotient of the 
participant’s estimate of the number of times RAE requested and 
annotation by the actual number of interactions, will be calculated [42]. 
This measure indirectly assesses the patient’s overall satisfaction with a 
technological system, and serves as a segregate measure of usability and 
acceptability. Low RSC (<1.0) correlates with increased participant 
satisfaction, while high RSC (>1.0) reflects poor usability of a technology. 
Qualitative data analysis 
Thematic analysis will be applied to exit interview and focus group 
qualitative data. The coding structure will initially be developed based on 
deductive codes from the interview guide, and then inductive codes will 
be added after review of the interview transcripts. Once the coding scheme 
is developed, each transcript will be double coded by two investigators 
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independently. After the transcripts are compared to ensure 
comprehensiveness of coding, the agreed-upon codes will be entered into 
qualitative data analysis software (NVivo, QRS International, Burlington, 
MA, USA). Resultant summaries arising from each code will be used to 
adapt and refine RAE components, interaction parameters, and other 
technology features. 
Aim 2: Randomized Controlled Trial 
After optimization of the RAE system in Aim 1, we will deploy the 
technology in a multi-site randomized controlled trial to measure impact 
on relapse rates, engagement/retention in treatment programs, and 
functioning/quality of life. Data from this Aim 2 pivotal study will be used 
to apply for FDA approval for the RAE system. During the RCT, the RAE 
system will be deployed as a part of SUD treatment programs at multiple 
outpatient sites nationwide. The goal is for RAE to be a tool that clinicians 
and patients can use to augment their treatment program; as such, in this 
phase, participants (clinician-patient dyads) will be provided with 
electronic instructional materials on the app, clinical portal and device, 
but study staff will otherwise not interfere with routine treatment 
protocols. 
We will recruit N = 300 participants across the same five study sites 
sampled in Aim 1. The exact expected effect size of the intervention is 
difficult to calculate given the wide range of reported values for relapse 
rates for individuals in recovery from SUD. Using the NIH reported rate of 
relapse (40–60%), we conservatively estimate a mean rate of relapse in the 
control population is 50%. A sample size of 264 participants (study wide) 
would then allow us to detect a 10% decrease in relapse rate in the RAE 
group with 90% power and 5% alpha level. We have inflated the sample 
size by approximately 15% to account for attrition and loss to follow up. 
Inclusion and exclusion criteria will be identical to Aim 1 (described 
above). Participants will be randomized in a 1:1 fashion using a computer-
generated stratified randomization sequence to RAE plus standard 
treatment vs standard treatment alone (control). Participants in control 
group will receive a Garmin Vivosmart 4 wearable sensor to control for 
any effect of general health and wellness monitoring with a wearable, but 
will not have access to other RAE components. Given that the use of the 
RAE system is physically obvious, there will be no blinding with the 
exception of the standardized assessments for quality of life and 
functional status, and follow up data collection tools (described above): 
These tools will be administered and scored by blinded study staff to 
reduce the opportunity for bias in these outcome measures. 
The primary outcome for the RCT will be relapse to substance use at 3, 
6, and 12 months defined as (1) self-reported use of the substance they are 
in treatment for, (2) a positive urine drug screen for the same substance 
or (3) provider confirmed return to use. The secondary outcomes will be: 
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retention in treatment program and change in baseline scores on the 
WHOQOL, BASIS-24 and BAM scales at 3, 6, and 12 months. 
Data Analysis  
We will collect measures identical to those outlined in Aim 1, and will 
consult machine learning analysis and qualitative analysis to refine the 
detection algorithms and the quality of the intervention. The primary 
analysis for Aim 2 will be an intention-to- treat analysis to evaluate the 
impact of RAE on relapse to substance use, however we will also perform 
a per-protocol analysis. We will compare overall rates of relapse, and will 
determine relative risk of relapse in the RAE group vs control group. We 
use logistic regression models to adjust for treatment center, SUD subtype, 
treatment type (MOUD vs non-MOUD), age and gender. We will also 
compare change in scores of psychosocial functioning assessments over 
time in RAE users vs controls, using time series analysis and adjusting for 
the same for covariates. 
Limitations 
We acknowledge several limitations inherent in our study design and 
of the RAE system. First, the validation of the system using self-reported 
symptoms (craving/stress) as the gold standard presents opportunities for 
misclassification; for example, if a user is experiencing a subtle stress 
event that is not detected by RAE and that they do not recognize and 
acknowledge, this represents a missed false negative. However, as the 
individual uses RAE for a longer period of time, the goal is to use machine 
learning to improve detection of users’ stress and cravings to minimize 
false negatives. Second, the current protocol aims to evaluate the efficacy 
of RAE for a 30 day use period, although it is unknown what the optimal 
dose/duration of the intervention is. Future studies will need to address 
the impact of length and timing (with respect to the initiation of treatment) 
of RAE on its effectiveness. Third, RAE currently relies on and intact 
support system; challenges experienced by users who lack support 
structure will need to be addresses separately. 
As with all mHealth interventions, barriers to user engagement, 
specifically privacy and trust issues from the end user perspective, could 
limit efficacy if not addressed. From a technical perspective, RAE provides 
HIPPA compliant data management in a secure environment, which is 
expected to alleviate concerns from treatment providers. But for 
individuals in recovery from SUD, regulatory compliance standards alone 
may not be sufficient to alleviate privacy concerns. We believe that RAE 
will be more effective as an accountability tool that individuals in recovery 
can use to partner with providers, rather than mandatory monitor or “big 
brother.” To set this tone (and to build trust), we have implemented several 
strategies. The system is an opt-in technology; if a user wants to halt data 
collection, they can simply remove the sensor and/or turn off the app. Non-
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compliance will be apparent to their treatment provider and will raise 
questions, but is always an option. The GPS location feature, which is 
arguably the most invasive, can also be turned off at the client/treating 
providers discretion. Ongoing and future work will need to continuously 
address privacy and trust issues as a central component of the user 
experience and design to optimize engagement and, in turn, the 
opportunity for efficacy.  
DISCUSSION 
There is an urgent need for novel strategies to combat the growing SUD 
epidemic. mHealth technologies provide a means for individuals in 
recovery to consistently track physiologic and behavioral markers of risk 
while allowing the opportunity to for just-in time adaptive interventions 
and support. The development of the RAE system provides a novel tool for 
individuals with SUD, the clinicians who care for them, and the scientific 
community/mHealth research space.  
For the individual with SUD in recovery, the potential benefits of RAE 
include automated detection of high-risk events, de-escalation tools, 
contact with support systems, and accountability tracking. The ultimate 
goal is for these tools to provide the user valuable insight into their own 
behavior, opportunities for self-reflection, and a sense of connectedness 
and support.  
For SUD treatment clinicians, the potential in the RAE system lies in the 
opportunity to monitor patient risk levels and visualize data to understand 
trends and triggers, many of which may not be readily apparent to the user 
or clinician. This ability of clinicians to use objective measures of risk to 
tailor interventions for individuals in recovery could prevent relapse, 
improve rates of sustained recovery, and save lives compared to current 
treatment paradigms. Mobile health tools such as RAE are a particularly 
attractive way for clinicians to connect with patients in the current 
challenges of COVID-19 related social distancing protocols, making study 
of this approach particularly timely [43,44]. 
For the general scientific community and knowledge base, the 
refinement of digital biomarkers of craving and stress developed through 
RAE have the potential to enhance our understanding of the biological 
underpinnings of these phenomenon, and of the mechanics of addiction, 
facilitating the provision of personalized medicine. If successful, outcomes 
from this work would lay the groundwork for other real-time, automated 
behavioral interventions that are triggered by digital biomarkers. This 
translates to a personalized intervention approach, an area that 
behavioral research experts have identified as a critical next step for the 
field of drug abuse treatment. This novel digital intervention provides a 
plausibly low-cost mechanism to enhance the success of SUD treatment. 
Furthermore, RAE can also be tested as a stress management option for 
other high-risk populations with and without SUD, such as healthcare 
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providers, justice involved individuals, and those with other mental health 
diagnoses. 
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